Spots Global Cancer Trial Database for ovarian carcinoma
Every month we try and update this database with for ovarian carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| HOPE-Genomics Intervention for the Improvement of Cancer Patient Knowledge of Genomics | NCT04905082 | Breast Carcinom... Colorectal Carc... Lung Carcinoma Malignant Solid... Ovarian Carcino... Pancreatic Carc... Prostate Carcin... | Best Practice Educational Int... Educational Int... Genomic Profile Survey Administ... | 18 Years - | City of Hope Medical Center | |
| Weekly Carboplatin/Docetaxel for Recurrent Ovarian/Peritoneal Cancer | NCT00214058 | Ovarian Carcino... Primary Periton... | Carboplatin Docetaxel | 18 Years - | University of Wisconsin, Madison | |
| Itraconazole in Advanced Ovarian Cancer | NCT05591560 | Ovarian Carcino... | Itraconazole ca... Placebo | 18 Years - 65 Years | Tanta University | |
| Intraperitoneal Paclitaxel and Carboplatin in the Treatment of Women With Carcinoma of Mullerian Origin | NCT00181701 | Ovarian Carcino... | Paclitaxel Carboplatin | 18 Years - | Massachusetts General Hospital | |
| Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian Primary Peritoneal Carcinoma | NCT00868192 | Ovarian Carcino... Primary Periton... | Pemetrexed Bevacizumab | 18 Years - | Washington University School of Medicine | |
| A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors | NCT03517488 | Melanoma Breast Carcinom... Hepatocellular ... Urothelial Carc... Squamous Cell C... Renal Cell Carc... Colorectal Carc... Non-small Cell ... Gastric or Gast... Endometrial Car... Mesothelioma Neuroendocrine ... Cervical Cancer Small Cell Lung... Squamous Cell C... Castration-Resi... Nasopharyngeal ... Cholangiocarcin... Basal Cell Carc... Ovarian Carcino... Fallopian Tube ... Thymoma Thymic Carcinom... Squamous Cell C... Vulvar Carcinom... Solid Tumors Wi... Malignant Adnex... Non-squamous Ce... | XmAb20717 | 18 Years - | Xencor, Inc. | |
| REGorafenib vsTamoxifen in Patients With Platinum-sensitive OVARian Carcinoma and Isolated Biological Progression | NCT02584465 | Ovarian Carcino... | Tamoxifen Regorafenib | 18 Years - | ARCAGY/ GINECO GROUP | |
| Maintenance Treatment for Ovarian Carcinoma in Remission by an Antiangiogenic Treatment Strategy | NCT01175772 | Ovarian Carcino... | Cytophosphan, C... | 20 Years - 80 Years | HaEmek Medical Center, Israel | |
| Evaluation of Pretreatment Sarcopenia in Patients With Inoperable High-grade Ovarian Carcinoma as Part of Optimised Management | NCT05415527 | Ovarian Carcino... | Presence of sar... | 18 Years - | Institut Bergonié | |
| Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction | NCT01366144 | Breast Carcinom... Carcinoma of Un... Endometrial Car... Esophageal Carc... Liver Failure Lung Carcinoma Malignant Head ... Malignant Testi... Melanoma Metastatic Mali... Ovarian Carcino... Renal Failure Unresectable Ma... Urothelial Carc... | Carboplatin Laboratory Biom... Paclitaxel Pharmacological... Veliparib | 18 Years - | National Cancer Institute (NCI) | |
| Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | NCT00989651 | Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Ovarian Brenner... Ovarian Carcino... Ovarian Carcino... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Seromuc... Ovarian Serous ... Ovarian Transit... Ovarian Undiffe... Primary Periton... Primary Periton... Stage IIA Fallo... Stage IIA Ovari... Stage IIB Fallo... Stage IIB Ovari... Stage IIC Fallo... Stage IIC Ovari... Stage IIIA Fall... Stage IIIA Ovar... Stage IIIA Prim... Stage IIIB Fall... Stage IIIB Ovar... Stage IIIB Prim... Stage IIIC Fall... Stage IIIC Ovar... Stage IIIC Prim... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar... | Bevacizumab Carboplatin Cisplatin Laboratory Biom... Paclitaxel Veliparib | 18 Years - | National Cancer Institute (NCI) | |
| Metabolite Levels in Ovarian Cancer Patients Receiving Maintenance PARP Inhibitors | NCT04917744 | Ovarian Carcino... | Biospecimen Col... Laboratory Biom... Medical Chart R... | - | Mayo Clinic | |
| Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002) | NCT05446870 | High-grade Sero... Ovarian Carcino... | Pembrolizumab Paclitaxel Carboplatin Avastin MK-4830 Docetaxel | 18 Years - | Merck Sharp & Dohme LLC | |
| Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies | NCT02419495 | Advanced Malign... Clinical Stage ... Clinical Stage ... Fallopian Tube ... Metastatic Lung... Metastatic Mali... Metastatic Mela... Metastatic Rena... Ovarian Carcino... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Primary Periton... Stage III Lung ... Stage III Renal... Stage IIIA Lung... Stage IIIB Lung... Stage IIIC Lung... Stage IV Lung C... Stage IV Renal ... Stage IVA Lung ... Stage IVB Lung ... Triple-Negative... Unresectable Lu... Unresectable Me... Unresectable Re... | Capecitabine Carboplatin Cyclophosphamid... Doxorubicin Eribulin Fluorouracil Ipilimumab Irinotecan Hydr... Leucovorin Calc... Nivolumab Olaparib Oxaliplatin Paclitaxel Pembrolizumab Pemetrexed Selinexor Topotecan | 18 Years - | M.D. Anderson Cancer Center | |
| Trial of Chemotherapy in Ovarian, Fallopian Tube and Peritoneal Carcinoma | NCT01519869 | Primary Periton... Ovarian Carcino... Fallopian Tube ... | neoadjuvant che... | 18 Years - | University of Kentucky | |
| Clinical Outcomes for Offering Genetic Testing in a Tiered Approach | NCT04902144 | Breast Carcinom... Colon Carcinoma Malignant Solid... Ovarian Carcino... Pancreatic Carc... Prostate Carcin... | Electronic Heal... Questionnaire A... Behavioral Inte... | 19 Years - 90 Years | Fred Hutchinson Cancer Center | |
| A Trial Evaluating Efficacy and Safety of Oxaliplatin With 5-Fluorouracil in Patients With Recurrent Ovarian Carcinoma | NCT01481701 | Ovarian Carcino... Relapse | Oxaliplatin oxaliplatin | 18 Years - | Jules Bordet Institute | |
| RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression | NCT06420973 | Ovarian Carcino... Fallopian Tube ... Primary Periton... | RC48+carboplati... | 18 Years - 75 Years | Peking University Cancer Hospital & Institute | |
| Intraperitoneal LSTA1 in CRS-HIPEC | NCT06216561 | Colorectal Canc... Ovarian Carcino... Appendix Cancer Peritoneal Meta... | CRS-HIPEC + LST... CRS-HIPEC alone | 18 Years - | University of California, San Diego | |
| Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family Members | NCT02194387 | Body Mass Index... BRCA1 Gene Muta... BRCA2 Gene Muta... Breast Carcinom... Cancer Survivor Chronic Lymphoc... Fatigue Health Status U... Lynch Syndrome Ovarian Carcino... Overweight | Dietary Interve... Dietary Interve... Internet-Based ... Internet-Based ... Laboratory Biom... Questionnaire A... Telephone-Based... Telephone-Based... | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers | NCT05544929 | Carcinoma, Non-... Cutaneous Melan... Carcinoma, Rena... Carcinoma, Ovar... Nasopharyngeal ... Carcinoma, Thym... Anal Cancer Mesothelioma Esophagogastric... High Microsatel... Squamous Cell C... Triple Negative... | KFA115 pembrolizumab | 18 Years - | Novartis | |
| Photoacoustic Imaging in Detecting Ovarian or Fallopian Tube Cancer | NCT02530606 | Fallopian Tube ... Ovarian Carcino... | Photoacoustic I... | 18 Years - 80 Years | Stanford University | |
| AMT-151 in Patients With Selected Advanced Solid Tumours | NCT05498597 | Advanced Solid ... Advanced Cancer Advanced Carcin... Ovarian Cancer Ovarian Carcino... Ovarian Epithel... Ovarian Endomet... Endometrial Can... Endometrial Ade... Endometrial Ser... Endometrial End... Endometrial Cle... Lung Adenocarci... Triple Negative... Pancreatic Duct... Malignant Pleur... Ovarian Clear C... Ovarian Clear C... Ovarian Mucinou... | AMT-151 | 18 Years - | Multitude Therapeutics Inc. | |
| Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer | NCT02345265 | Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Ovarian Carcino... Ovarian High Gr... Ovarian High Gr... Primary Periton... Primary Periton... Primary Periton... | Biopsy Biospecimen Col... Cediranib Malea... Computed Tomogr... Echocardiograph... Magnetic Resona... Multigated Acqu... Olaparib Questionnaire A... | 18 Years - | National Cancer Institute (NCI) | |
| Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | NCT02159989 | Advanced Malign... Fibrolamellar C... Metastatic Mali... Ovarian Carcino... Pancreatic Neur... Recurrent Malig... Refractory Mali... Unresectable So... | Sapanisertib Ziv-Aflibercept | 18 Years - | National Cancer Institute (NCI) | |
| Skeletal Muscle Energy Metabolism in Women With Weight Loss and Ovarian and/or Endometrial Cancer With Weight Loss | NCT03027479 | Weight Loss Ovarian Carcino... Endometrial Car... | Samples | 18 Years - | University Hospital, Tours | |
| A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE) | NCT05429970 | Ovarian Cancer Ovarian Carcino... Stage II Ovary ... Stage II Ovaria... Stage III Ovary... Stage III Ovari... Stage IV Ovary ... Stage IV Ovaria... Epithelial Ovar... Fallopian Tube ... Stage II Fallop... Stage III Fallo... Stage IV Fallop... Primary Periton... | Mind-body resil... Music therapy Propranolol Etodolac | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors | NCT06172478 | Advanced Solid ... Melanoma Head and Neck C... Gastric Cancer Ovarian Carcino... Cervical Cancer Endometrial Can... Bladder Cancer Esophageal Canc... Pancreatic Carc... Prostate Cancer | HER3-DXd | 18 Years - | Daiichi Sankyo | |
| Intraperitoneal Paclitaxel and Carboplatin in the Treatment of Women With Carcinoma of Mullerian Origin | NCT00181701 | Ovarian Carcino... | Paclitaxel Carboplatin | 18 Years - | Massachusetts General Hospital | |
| Milademetan in Advanced/Metastatic Solid Tumors | NCT05012397 | Solid Tumors Head and Neck C... Cholangiocarcin... Sarcoma Lung Adenocarci... Bladder Urothel... Stomach Adenoca... Breast Cancer I... Ovarian Carcino... Cervical Cancer Non Small Cell ... Gastric Cancer Biliary Tract C... Melanoma Pancreas Cancer MDM2 Gene Ampli... Testicular Germ... Adrenocortical ... | RAIN-32 | 18 Years - | Rain Oncology Inc | |
| A Study to Compare CAELYX With Topotecan HCL in Patients With Recurrent Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy | NCT01840943 | Epithelial Ovar... | CAELYX Topotecan HCl | 18 Years - | Xian-Janssen Pharmaceutical Ltd. | |
| Maintenance Treatment for Ovarian Carcinoma in Remission by an Antiangiogenic Treatment Strategy | NCT01175772 | Ovarian Carcino... | Cytophosphan, C... | 20 Years - 80 Years | HaEmek Medical Center, Israel | |
| Skeletal Muscle Energy Metabolism in Women With Weight Loss and Ovarian and/or Endometrial Cancer With Weight Loss | NCT03027479 | Weight Loss Ovarian Carcino... Endometrial Car... | Samples | 18 Years - | University Hospital, Tours | |
| Dietary Magnesium in Preventing Low Blood Magnesium Levels in Patients With Ovarian Cancer Receiving Carboplatin Chemotherapy | NCT04310826 | Ovarian Carcino... | Dietary Interve... Media Intervent... Telephone-Based... | 18 Years - | M.D. Anderson Cancer Center | |
| IGFBP-3 in Ovarian Cancer Invasion | NCT00154986 | Ovarian Carcino... | immunohistochem... | 21 Years - 80 Years | National Taiwan University Hospital | |
| Fractional CO2 Laser Therapy in Minimizing Genitourinary Syndrome of Menopause in Gynecological Cancer Survivors | NCT03372720 | Cervical Carcin... Dyspareunia Endometrial Car... Ovarian Carcino... Vaginal Carcino... Vaginal Dryness Vulvar Carcinom... | Laser Therapy Questionnaire A... Sham Interventi... | - | Ohio State University Comprehensive Cancer Center | |
| A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors | NCT04442126 | Advanced Solid ... Non-small Cell ... Colorectal Canc... Squamous Cell C... Ovarian Carcino... Peritoneal Carc... Fallopian Tube ... Head and Neck S... Triple Negative... | NM21-1480 | 18 Years - | Numab Therapeutics AG | |
| p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246 | NCT02098343 | Platinum Sensit... | APR-246 Carboplatin and... | 18 Years - | Aprea Therapeutics | |
| Prophylactic Salpingectomy With Delayed Oophorectomy | NCT01907789 | Ovarian Carcino... | Ovarian Cancer ... Prophylactic Sa... Risk-Reducing S... Questionnaire Transvaginal Ul... Phone Call | 30 Years - 47 Years | M.D. Anderson Cancer Center | |
| Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian Primary Peritoneal Carcinoma | NCT00868192 | Ovarian Carcino... Primary Periton... | Pemetrexed Bevacizumab | 18 Years - | Washington University School of Medicine | |
| Albumin-bound Paclitaxel and Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer | NCT05310344 | Ovarian Carcino... Platinum-resist... Recurrent Ovari... Albumin-bound P... Bevacizumab Survival Outcom... Adverse Events | Albumin-bound p... | 18 Years - 75 Years | Peking Union Medical College Hospital | |
| Bioequivalence Study of SPARC147609 in Patients With Ovarian Cancer | NCT00862355 | Ovarian Carcino... | SPARC147609 Reference147609 | 18 Years - | Sun Pharma Advanced Research Company Limited | |
| Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer (EOC): A Phase III Randomized Study | NCT00715286 | Ovarian Carcino... | timing of surge... timing of surge... | 20 Years - 65 Years | All India Institute of Medical Sciences, New Delhi | |
| Topotecan in Combination With Pemetrexed in Patients With Advanced Malignancies | NCT00315861 | Ovarian Cancer Endometrial Can... Cervical Cancer Lung Cancer | pemetrexed topotecan | 18 Years - | SCRI Development Innovations, LLC | |
| Neoadjuvant Immunotherapy in Brain Metastases | NCT04434560 | Brain Metastase... | Nivolumab Ipilimumab | 18 Years - | Duke University | |
| Clinical Trial of Docetaxel in Combination With Gemcitabine in Platinum-Resistant Ovarian Cancer and Primary Peritoneal Carcinoma | NCT00183794 | Ovarian Carcino... Peritoneal Neop... | Docetaxel and G... | 18 Years - | University of Southern California | |
| Intraperitoneal Paclitaxel and Carboplatin in the Treatment of Women With Carcinoma of Mullerian Origin | NCT00181701 | Ovarian Carcino... | Paclitaxel Carboplatin | 18 Years - | Massachusetts General Hospital | |
| Trabectedin Combined With Durvalumab in Patients With Advanced Pretreated Soft-tissue Sarcomas and Ovarian Carcinomas. | NCT03085225 | Ovarian Carcino... Soft Tissue Sar... | Combination of ... | 18 Years - | Institut Bergonié | |
| A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors | NCT05001347 | Ovarian Cancer Head and Neck C... Non Small Cell ... Gastrointestina... Triple Negative... Ovarian Carcino... | TJ004309 | 18 Years - | I-Mab Biopharma US Limited | |
| Cost of Cancer Risk Management in Women at Elevated Genetic Risk for Ovarian Cancer Who Participated on GOG-0199 | NCT01445275 | Fallopian Tube ... Hereditary Brea... Ovarian Carcino... Primary Periton... | Evaluation of C... Medical Chart R... Study of Socioe... | 30 Years - | GOG Foundation | |
| Sentinel Lymph Node Biopsy in Early-Stage Ovarian Cancer | NCT05927818 | Sentinel Lymph ... Ovarian Carcino... | Sentinel lymph ... | 18 Years - 90 Years | Istanbul University | |
| Biomarkers in Patients With Previously Untreated Invasive Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | NCT01295489 | Fallopian Tube ... Ovarian Carcino... Primary Periton... | Laboratory Biom... | 18 Years - | GOG Foundation | |
| A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients | NCT06028932 | Ovarian Carcino... | Sacituzumab gov... | 18 Years - | Yale University | |
| Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer | NCT00511992 | Advanced Ovaria... Primary Periton... Ovarian Carcino... | Avastin Paclitaxel Cisplatin | 18 Years - | University of Oklahoma | |
| A Study to Compare CAELYX With Topotecan HCL in Patients With Recurrent Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy | NCT01840943 | Epithelial Ovar... | CAELYX Topotecan HCl | 18 Years - | Xian-Janssen Pharmaceutical Ltd. | |
| PEP-DC and OC-DC Vaccine in High Grade Serous Ovarian Carcinoma | NCT05714306 | Ovarian Carcino... | PEP-DC1 OC-DC PEP-DC2 Low dose cyclop... | 18 Years - | Centre Hospitalier Universitaire Vaudois | |
| An Exercise Intervention Trial to Reduce Symptoms & Improve Clinical Outcomes of Platinum-Based Treatment in Ovarian Cancer Patients | NCT02878980 | Ovarian Carcino... | Exercise Interv... Laboratory Biom... Quality-of-Life... Questionnaire A... | - | City of Hope Medical Center | |
| A Multi-center Study of VAL-083 in Patients With Recurrent Platinum Resistant Ovarian Cancer | NCT03281681 | Ovarian Cancer | VAL-083, Dianhy... | 18 Years - | Kintara Therapeutics, Inc. | |
| TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors | NCT03756818 | Advanced Malign... Ovarian Carcino... Refractory Mali... Refractory Ovar... | Mivavotinib Paclitaxel Pharmacokinetic... | 18 Years - | M.D. Anderson Cancer Center | |
| Impact of Fas/FasL in Chemotherapy Response in Epithelial Ovarian Carcinoma | NCT02297958 | Ovarian Carcino... | 18 Years - | Rennes University Hospital | ||
| Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Ovarian Carcinoma | NCT02487693 | Ovarian Carcino... | Radiofrequency ... Cytokine-induce... | 30 Years - 70 Years | The First People's Hospital of Changzhou | |
| LDFWART With Docetaxel in Patients With Platinum-Resistant Recurrent Ovarian Carcinoma | NCT02083536 | Ovarian Cancer Ovarian Carcino... Recurrent Ovari... Recurrent Ovari... | Low Dose Fracti... Docetaxel | 18 Years - 80 Years | University of Miami | |
| Copper Cu 64-DOTA-B-Fab PET/CT in Imaging Patients With Ovarian and Breast Cancer | NCT02708511 | Ovarian Carcino... Breast Carcinom... | Computed Tomogr... Copper Cu 64-DO... Laboratory Biom... Pharmacological... Positron Emissi... | 18 Years - | Stanford University | |
| Cost of Cancer Risk Management in Women at Elevated Genetic Risk for Ovarian Cancer Who Participated on GOG-0199 | NCT01445275 | Fallopian Tube ... Hereditary Brea... Ovarian Carcino... Primary Periton... | Evaluation of C... Medical Chart R... Study of Socioe... | 30 Years - | GOG Foundation | |
| Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002) | NCT05446870 | High-grade Sero... Ovarian Carcino... | Pembrolizumab Paclitaxel Carboplatin Avastin MK-4830 Docetaxel | 18 Years - | Merck Sharp & Dohme LLC | |
| MLN8237 for Treatment of Participants With Ovarian, Fallopian Tube, or Peritoneal Carcinoma | NCT00853307 | Ovarian Carcino... | Alisertib | 18 Years - | Takeda | |
| Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy | NCT00377429 | Ovarian Cancer | catumaxomab | 18 Years - | Neovii Biotech | |
| Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer | NCT05494580 | Ovarian Cancer Ovarian Carcino... Platinum-resist... Fallopian Tube ... Primary Periton... | Pamiparib Surufatinib | 18 Years - 75 Years | Sun Yat-sen University | |
| Prophylactic Salpingectomy With Delayed Oophorectomy | NCT01907789 | Ovarian Carcino... | Ovarian Cancer ... Prophylactic Sa... Risk-Reducing S... Questionnaire Transvaginal Ul... Phone Call | 30 Years - 47 Years | M.D. Anderson Cancer Center | |
| Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer | NCT00511992 | Advanced Ovaria... Primary Periton... Ovarian Carcino... | Avastin Paclitaxel Cisplatin | 18 Years - | University of Oklahoma | |
| Ultrasound-guided Tru-Cut Biopsy in Pelvic Masses. | NCT05610501 | Pelvic Cancer Ovarian Cancer Cervical Cancer Uterus Cancer Endometrial Can... Ovarian Neoplas... Ovarian Carcino... Sarcoma Uterus Metastatic Canc... | Ultrasound guid... | 18 Years - | Universitaire Ziekenhuizen KU Leuven | |
| Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer (EOC): A Phase III Randomized Study | NCT00715286 | Ovarian Carcino... | timing of surge... timing of surge... | 20 Years - 65 Years | All India Institute of Medical Sciences, New Delhi | |
| A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer | NCT05200364 | Ovarian Cancer Ovarian Carcino... Ovary Cancer Fallopian Tube ... Primary Periton... | STRO-002 Bevacizumab | 18 Years - | Sutro Biopharma, Inc. | |
| Whole-body Diffusion MRI for Staging, Response Prediction and Detecting Tumor Recurrence in Patients With Ovarian Cancer | NCT01657747 | Ovarian Carcino... | Whole body diff... | - | Universitaire Ziekenhuizen KU Leuven | |
| Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer (CHIPPI) | NCT03842982 | Ovary Neoplasms Ovarian Cancer Ovarian Carcino... | HIPEC | 18 Years - 76 Years | Centre Oscar Lambret | |
| Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers | NCT03748186 | Ovarian Cancer Ovarian Carcino... Ovary Cancer Endometrial Can... Endometrioid Ad... Fallopian Tube ... Primary Periton... | STRO-002 | 18 Years - | Sutro Biopharma, Inc. | |
| LDFWART With Docetaxel in Patients With Platinum-Resistant Recurrent Ovarian Carcinoma | NCT02083536 | Ovarian Cancer Ovarian Carcino... Recurrent Ovari... Recurrent Ovari... | Low Dose Fracti... Docetaxel | 18 Years - 80 Years | University of Miami | |
| Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | NCT02159989 | Advanced Malign... Fibrolamellar C... Metastatic Mali... Ovarian Carcino... Pancreatic Neur... Recurrent Malig... Refractory Mali... Unresectable So... | Sapanisertib Ziv-Aflibercept | 18 Years - | National Cancer Institute (NCI) | |
| Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers | NCT03748186 | Ovarian Cancer Ovarian Carcino... Ovary Cancer Endometrial Can... Endometrioid Ad... Fallopian Tube ... Primary Periton... | STRO-002 | 18 Years - | Sutro Biopharma, Inc. | |
| A Trial Evaluating Efficacy and Safety of Oxaliplatin With 5-Fluorouracil in Patients With Recurrent Ovarian Carcinoma | NCT01481701 | Ovarian Carcino... Relapse | Oxaliplatin oxaliplatin | 18 Years - | Jules Bordet Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
